BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:Can anti-cancer immunotherapeutics be repurposed to kill parasites
 ? - Paula MacGregor\, Department of Biochemistry
DTSTART:20170216T131000Z
DTEND:20170216T140000Z
UID:TALK71153@talks.cam.ac.uk
CONTACT:KC Sivaramakrishnan
DESCRIPTION:One of the key goals in the design of new anti-cancer therapeu
 tics is to kill the cancer cells while limiting damage to the healthy cell
 s of the body. In pursuit of this goal\, anti-cancer antibody-drug conjuga
 tes (ADCs) are increasingly being developed. These immunotherapeutics conc
 entrate the drug specifically inside the cancer cell by combining an antib
 ody that targets the cancer cell surface with a cytotoxic drug.\n\nIn para
 llel\, one of the goals in the design of novel therapeutics against protoz
 oan parasites is to destroy the invading cells without causing damage to t
 he host cells. It is logical\, therefore\, that ADCs could also provide a 
 new class of therapeutic agents against protozoan pathogens. Further\, the
 re is clear scope for piggy-back drug development alongside anti-cancer AD
 Cs by varying only cell-specificity.\n\nI will discuss the use of the Afri
 can trypanosome as a proof-of- principle model for the use of anti-cancer 
 ADCs against parasites.
LOCATION:The Richard King Room\, Darwin College
END:VEVENT
END:VCALENDAR